Published in Curr Drug Targets on April 01, 2003
The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis. Cell (2009) 2.80
Suppression of PTEN expression by NF-kappa B prevents apoptosis. Mol Cell Biol (2004) 2.01
Binding and phosphorylation of par-4 by akt is essential for cancer cell survival. Mol Cell (2005) 1.82
Identification of a unique core domain of par-4 sufficient for selective apoptosis induction in cancer cells. Mol Cell Biol (2003) 1.49
Phosphorylation of Par-4 by protein kinase A is critical for apoptosis. Mol Cell Biol (2005) 1.38
Apoptosis by Par-4 in cancer and neurodegenerative diseases. Exp Cell Res (2003) 1.34
Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. J Biol Chem (2003) 1.34
Role of tumor necrosis factor-alpha and TRAIL in high-dose radiation-induced bystander signaling in lung adenocarcinoma. Cancer Res (2007) 1.28
Cancer resistance in transgenic mice expressing the SAC module of Par-4. Cancer Res (2007) 1.25
Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells. J Biol Chem (2005) 1.18
Suppression of PTEN expression is essential for antiapoptosis and cellular transformation by oncogenic Ras. Cancer Res (2007) 1.14
Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth. J Immunol (2007) 1.14
Chemoprevention of pancreatic cancer: characterization of Par-4 and its modulation by 3,3' diindolylmethane (DIM). Pharm Res (2008) 1.13
Mechanisms of apoptosis by the tumor suppressor Par-4. J Cell Physiol (2012) 1.13
RIP1 activates PI3K-Akt via a dual mechanism involving NF-kappaB-mediated inhibition of the mTOR-S6K-IRS1 negative feedback loop and down-regulation of PTEN. Cancer Res (2009) 1.08
Accuracy of self-reported tobacco assessments in a head and neck cancer treatment population. Radiother Oncol (2011) 1.07
The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective therapeutic target. Cancer Res (2006) 1.06
Novel mechanism of apoptosis resistance in cancer mediated by extracellular PAR-4. Cancer Res (2012) 1.06
The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-kappaB inhibition and enhanced by the presence of PTEN. Mol Cancer Ther (2007) 1.03
Regulation of cancer cell survival by Par-4. Ann N Y Acad Sci (2005) 1.03
Par-4 binds to topoisomerase 1 and attenuates its DNA relaxation activity. Cancer Res (2008) 1.00
Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis. Mol Cancer Ther (2008) 1.00
Systemic Par-4 inhibits non-autochthonous tumor growth. Cancer Biol Ther (2011) 0.99
Apoptosis and tumor resistance conferred by Par-4. Cancer Biol Ther (2008) 0.95
Par-4 inducible apoptosis in prostate cancer cells. J Cell Biochem (2004) 0.95
In lymphatic cells par-4 sensitizes to apoptosis by down-regulating bcl-2 and promoting disruption of mitochondrial membrane potential and caspase activation. Cancer Res (2002) 0.91
Endocrine expression of the active form of TGF-beta1 in the TGF-beta1 null mice fails to ameliorate lethal phenotype. Cytokine (2002) 0.89
Bcl-xL mediates a survival mechanism independent of the phosphoinositide 3-kinase/Akt pathway in prostate cancer cells. J Biol Chem (2003) 0.87
Targeting plasma membrane GRP78 for cancer growth inhibition. Cancer Biol Ther (2010) 0.87
Nicotinic modulation of therapeutic response in vitro and in vivo. Int J Cancer (2012) 0.87
The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells. Acta Neuropathol (2014) 0.79
Par(-4)oxysm in breast cancer. Cancer Cell (2013) 0.79
Molecular therapy intervention prospects in prostate cancer. Curr Pharm Des (2004) 0.78
Prostate apoptosis response-4 is involved in the apoptosis response to docetaxel in MCF-7 breast cancer cells. Int J Oncol (2013) 0.78
Exploiting the TSA connections to overcome apoptosis-resistance. Cancer Biol Ther (2005) 0.78
Regulation of Par-4 by oncogenic Ras. Methods Enzymol (2006) 0.76
ErbB4 targeting approaches for prostate cancer treatment. Cancer Biol Ther (2008) 0.76
"D" approach to prevent metastasis. Cancer Biol Ther (2007) 0.75
Par-4 prevents breast cancer recurrence. Breast Cancer Res (2013) 0.75
Cancer-selective apoptosis by tumor suppressor par-4. Adv Exp Med Biol (2014) 0.75